scholarly journals Parkinson’s Disease: Available Clinical and Promising Omics Tests for Diagnostics, Disease Risk Assessment, and Pharmacotherapy Personalization

Diagnostics ◽  
2020 ◽  
Vol 10 (5) ◽  
pp. 339 ◽  
Author(s):  
Oxana P. Trifonova ◽  
Dmitri L. Maslov ◽  
Elena E. Balashova ◽  
Guzel R. Urazgildeeva ◽  
Denis A. Abaimov ◽  
...  
Keyword(s):  
Risk Assessment ◽  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Neurodegenerative Disease ◽  
Disease Risk ◽  
Modern Medicine ◽  
Economic Problem ◽  
Prodromal Stage ◽  
Effective System ◽  
Diagnostics And Therapy

Parkinson’s disease is the second most frequent neurodegenerative disease, representing a significant medical and socio-economic problem. Modern medicine still has no answer to the question of why Parkinson’s disease develops and whether it is possible to develop an effective system of prevention. Therefore, active work is currently underway to find ways to assess the risks of the disease, as well as a means to extend the life of patients and improve its quality. Modern studies aim to create a method of assessing the risk of occurrence of Parkinson’s disease (PD), to search for the specific ways of correction of biochemical disorders occurring in the prodromal stage of Parkinson’s disease, and to personalize approaches to antiparkinsonian pharmacotherapy. In this review, we summarized all available clinically approved tests and techniques for PD diagnostics. Then, we reviewed major improvements and recent advancements in genomics, transcriptomics, and proteomics studies and application of metabolomics in PD research, and discussed the major metabolomics findings for diagnostics and therapy of the disease.

scholarly journals Biomarker in Parkinson’s Disease: Clinical and Biochemical Biomarker

2021 ◽  
Vol 39 (4) ◽  
pp. 287-297
Author(s):  
Ju-Young Lee ◽  
Hyeo-il Ma ◽  
Young Eun Kim
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Neurodegenerative Disease ◽  
Biological Tissue ◽  
Disease Course ◽  
Prodromal Stage ◽  
Successful Development ◽  
Disease Modifying Therapy ◽  
Clinical Biomarkers ◽  
Disease Modifying

Parkinson’s disease is a neurodegenerative disease compromising progressive motor and non-motor features for a long disease course. Although many drugs controlling parkinsonian symptoms were discovered, treatment with disease-modifying or halting effect was not developed to date. The exploration of reliable biomarkers would be helpful for better predicting disease progression and thereby successful development of disease-modifying therapy. In this review, we will review the clinical biomarkers in the prodromal stage and biomarkers using biological tissue in Parkinson’s disease.

Trichloroethylene and Parkinson’s Disease: Risk Assessment

2017 ◽  
Vol 55 (7) ◽  
pp. 6201-6214 ◽  
Author(s):  
Mei Liu ◽  
Eun-Joo Shin ◽  
Duy-Khanh Dang ◽  
Chun-Hui Jin ◽  
Phil Ho Lee ◽  
...  
Keyword(s):  
Risk Assessment ◽  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Disease Risk

scholarly journals The TOMM40 ‘523’ polymorphism in disease risk and age of symptom onset in two independent cohorts of Parkinson’s disease

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Megan C. Bakeberg ◽  
Madison E. Hoes ◽  
Anastazja M. Gorecki ◽  
Frances Theunissen ◽  
Abigail L. Pfaff ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Symptom Onset ◽  
Disease Risk ◽  
Age Of Onset ◽  
Sequencing Analysis ◽  
Age Related ◽  
Australian Cohort ◽  
Progression Markers ◽  
Age Related Cognitive Decline

AbstractAbnormal mitochondrial function is a key process in the pathogenesis of Parkinson’s disease (PD). The central pore-forming protein TOM40 of the mitochondria is encoded by the translocase of outer mitochondrial membrane 40 homologue gene (TOMM40). The highly variant ‘523’ poly-T repeat is associated with age-related cognitive decline and age of onset in Alzheimer’s disease, but whether it plays a role in modifying the risk or clinical course of PD it yet to be elucidated. The TOMM40 ‘523’ allele length was determined in 634 people with PD and 422 healthy controls from an Australian cohort and the Parkinson’s Progression Markers Initiative (PPMI) cohort, using polymerase chain reaction or whole genome sequencing analysis. Genotype and allele frequencies of TOMM40 ‘523’ and APOE ε did not differ significantly between the cohorts. Analyses revealed TOMM40 ‘523’ allele groups were not associated with disease risk, while considering APOE ε genotype. Regression analyses revealed the TOMM40 S/S genotype was associated with a significantly later age of symptom onset in the PPMI PD cohort, but not after correction for covariates, or in the Australian cohort. Whilst variation in the TOMM40 ‘523’ polymorphism was not associated with PD risk, the possibility that it may be a modifying factor for age of symptom onset warrants further investigation in other PD populations.

Parkinson’s disease risk score: moving to a premotor diagnosis

2011 ◽  
Vol 258 (S2) ◽  
pp. 311-315 ◽  
Author(s):  
Jürgen Winkler ◽  
Reinhard Ehret ◽  
Thomas Büttner ◽  
Ulrich Dillmann ◽  
Wolfgang Fogel ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Risk Score ◽  
Disease Risk ◽  
Disease Risk Score

PBPK/PD assessment for Parkinson’s disease risk posed by airborne pesticide paraquat exposure

2017 ◽  
Vol 25 (6) ◽  
pp. 5359-5368 ◽  
Author(s):  
Yi-Hsien Cheng ◽  
Wei-Chun Chou ◽  
Ying-Fei Yang ◽  
Chi-Wei Huang ◽  
Chun Ming How ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Disease Risk
Sign in / Sign up

Export Citation Format

Share Document